Sheldon Tse

Sheldon Tse

Areas of Practice

Dr. Sheldon Tse specializes in corporate finance, private equity transactions, mergers and acquisitions, and foreign direct investment projects, with a sharp focus on the PRC.

He has extensive experience in listed company work, corporate restructuring, takeovers, PRC regulatory work, and has handled many listings. He has also been involved in numerous PRC private equity transactions, foreign direct investment, and merger and acquisition projects. Dr. Tse's clients include listed companies, fund management houses, multinationals, large state-owned enterprises, and private enterprises based in the PRC.

Work Experience

Prior to joining King & Wood Mallesons in 2004, Dr. Tse served with a major international law firm for nearly 11 years, 4 of them as a partner.

In 1998, Dr. Tse became a member of the arbitrator's panel of the Guangzhou Arbitration Commission. He is a member of the Hong Kong Securities Institute. He was selected as a leading individual in Hong Kong in the Capital Markets category of The Asia Pacific Legal 500. Dr. Tse is the Honorary Legal Adviser to the China Review Monthly, a member of the Guizhou Provincial Committee of China People's Political Consultative Conference and a member of the Law Society of England and Hong Kong.

Dr. Tse received his LL.B. degree at Zhongshan University, Guangzhou, PRC, and his LL.M. and Ph.D. at the University of London in the United Kingdom. He is a practising solicitor in Hong Kong, a solicitor of the Supreme Court of England and Wales, and an Attorney-at-Law in the People's Republic of China. Dr. Tse is proficient in English, Mandarin, Cantonese, and other dialects.

Location

Legal insights

The Inland Revenue (Profits Tax Exemption for Funds) (Amendment) Bill 2018 has introduced notable benefits to Hong Kong’s tax regime for funds.

28 December 2018

The SFC recently started proceedings in the MMT against a listed company for its failure to make timely disclosure of price sensitive inside info.

14 December 2018

Read on for issues that biotech companies should watch out when planning a listing by Ch.18A of the HK Main Board.

28 September 2018

HKEX concludes on its consultation on Review of the Corporate Governance Code and Related Listing Rules and Guidance for Boards and Directors.

07 August 2018

This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

For more information on which cookies we use then please refer to our Cookie Policy.